WO1996038556A2

WO1996038556A2 - Deltap62, variants thereof, amino acid sequences coding therefor and their uses in gene therapy for cancer

Info

Publication number: WO1996038556A2
Application number: PCT/FR1996/000802
Authority: WO
Inventors: Fabien Schweighoffer; Bruno Tocque
Original assignee: Rhone-Poulenc Rorer S.A.
Priority date: 1995-06-01
Filing date: 1996-05-29
Publication date: 1996-12-05
Also published as: HUP9901346A3; NO975409D0; CA2219861A1; MX9708877A; IL118493A0; AU6129196A; BR9608632A; ZA964392B; SK161397A3; WO1996038556A3; FR2734826B1; US6544948B1; EP0828832A2; SK283071B6; CZ291533B6; FR2734826A1; HUP9901346A2; AU718889B2; JPH11506325A; KR19990022193A

Abstract

A novel polypeptide designated as ΔP62 or ΔSam68, variants thereof, the corresponding nucleic acid sequences, and uses thereof, particularly in gene therapy for cancer, are described.

Description

ΔP62. ITS VARIANTS. NUCLEIC SEQUENCES AND THEIR

USES

The present invention relates to a new polypeptide designated ΔP62, its variants, the corresponding nucleic sequences, and their therapeutic uses, in particular in anti-cancer gene therapy.

Different genes, called oncogenes and suppressor genes, are involved in the control of cell division. Among these, the ras genes, and their products generally designated p21 proteins, play a key role in controlling cell proliferation in all the eukaryotic organisms where they have been sought. In particular, it has been shown that certain specific modifications of these proteins cause them to lose their normal control and lead them to become oncogenic. Thus, a large number of human tumors have been associated with the presence of modified ras genes. Likewise, overexpression of these p21 proteins can lead to disruption of cell proliferation. Understanding the exact role of these p21 proteins in cells, their mode of operation and their characteristics therefore constitutes a major challenge for the understanding and therapeutic approach of carcinogenesis.

In vivo, we do not know the precise nature of the events responsible for the transduction of the signal initiated by the p21 proteins. However, an increasing number of results underlines the multiplicity of effectors which interact directly and preferentially with the active form (linked to GTP) of ras proteins. Among these effectors, the GAP protein was the first whose involvement in transduction signal has been documented. It is a cytosolic protein present in all eukaryotic organisms which has the ability to greatly accelerate the hydrolysis of GTP, linked to the normal protein. It has two areas ensuring distinct functions. Its carboxy-terminal end carries the catalytic activity which interacts with the p21 proteins and which increases their GTPase activity. At its other end, downstream of the N-terminal part, is a juxtaposition of SH2 and SH3 domains which participate in the transduction of the message and interact with other proteins. Among these proteins are two proteins, p62 and p190, of 62kDa and 190 kDa respectively, which are strongly phosphorylated to tyrosine. These two proteins form a specific complex with GAP and are immunoprecipitated by antibodies directed against different epitopes of GAP. We know in particular that it is at the level of the SH2 domains of GAP that the interactions of p62 with GAP take place. Amino acids 271 to 443 of p62 contain phosphorylated tyrosines and appear to be involved in these interactions. These same phosphorylations also seem to participate in interactions between p62 and the GRB2 adapter. On the other hand, throughout the sequence of p62, are distributed proline-rich consensus sites which participate in the binding to the SH3 domains of the tyrosine kinases of the src family as well as of the phospholipase Gy.

The p62 protein (or even Sam68) has been identified by Wong et al. (Cell 69 (1992) 551). It contains 443 amino acids, the sequence of which has been described in the literature (see SEQ ID No. 1). In addition to the characteristics mentioned above, the p62 protein has several characteristics specific to hnRNP ("heterogeneous nuclear RiboNucleoProtein"):

- it is rich in glycines - it has regions rich in arginines

- in addition, its amino acids 145 to 247 define a region of strong homology with an hnRNP previously described, GRP33. This region contains a consensus RNA binding site homologous to that contained in hnRNP K. This consensus site is designated KH domain (KH = hnRNPK Homolog). The conserved residues are essential for binding to RNAs and the impact of the non-integrity of this domain in a pathology has been shown for FMR1 which is the product of the gene associated with mental retardation which is observed in X-fragile syndrome ( Siomi et al., Cell 77 (1994) 33). The present invention resides in particular in demonstrating the importance of the protein p62 (Samδδ) in cell proliferation and death. It arises more particularly from the demonstration that p62 derivatives are capable of interfering in the process of cell transformation, and in particular of inhibiting the signals transduced by the ras and src proteins. It also results from the particularly surprising demonstration that these derivatives are also endowed with apoptotic properties, and therefore capable of inducing cell death.

A first object of the invention therefore relates to any p62 derivative capable of at least partially inhibiting the interaction between a GAP protein and p62. Preferably, the derivatives according to the invention are capable of at least partially inhibiting the oncogenic power of the ras and / or src proteins. Again more preferably, the derivatives according to the invention are capable of inducing cell death by apoptosis. The derivatives according to the invention are also characterized by the loss of the ability to interact with the RNA of p62.

The present invention describes in particular the detection, cloning and characterization of a natural isoform of the protein p62. This isoform, designated Δp62 (or ΔSamβδ), has a deletion in the zone of homology to the GRP33 protein, which covers the KH domain. Due to this deletion, Δp62 does not have all of the properties of p62. Thus, Δp62 has an interaction domain with GAP and GRB2 intact as well as the various sequences rich in prolines partners of SH3 (Figure 1). However, Δp62 is no longer able to interact with nucleic acids due to the deletion of the domain of homology to the GRP33 protein. The Applicant has also shown that the transfer of the Δp62 cDNA into different normal or tumor cell models opposes the cooperation between p62 and Ras and inhibits the signals transduced by the normal and oncogenic Ras proteins. Overexpressed, Δp62 therefore interferes with the proliferation and differentiation processes and leads, in the various cell models, to cell death by apoptosis.

According to a preferred embodiment, the invention relates more particularly to any p62 derivative carrying at least one deletion in the region of homology to the GRP33 protein. More particularly, the derivatives according to the invention comprise at least one deletion in the region between residues 145 to 247 of the protein p62 as shown in the sequence SEQ ID No. 1, and which covers the KH domain. The deletion advantageously relates to more than 10 amino acids and, more preferably, to more than 30 acids amines. It can relate to one or more sites inside this region, as soon as the resulting derivative exhibits the properties described above.

In a particularly advantageous manner, the derivative according to the invention is a polypeptide comprising all or part of the sequence SEQ ID No. 2 or a variant thereof. The term variant within the meaning of the invention denotes any polypeptide whose structure is distinguished from the sequence SEQ ID No. 2 by one or more modifications of a genetic, biochemical and / or chemical nature. It may in particular be any mutation, substitution, deletion, addition and / or modification of one or more residues. Such derivatives can be generated for different purposes, such as in particular that of increasing the affinity of the peptide for its interaction site, that of improving its production levels, that of increasing its resistance to proteases or of '' improve its passage through cell membranes, that of increasing its therapeutic efficacy or reducing its side effects, or that of giving it new pharmacokinetic and / or biological properties. Advantageously, the variants include deletions or mutations relating to amino acids the presence of which is not decisive for the activity of the derivative. Such amino acids can be identified, for example, by cell activity tests as described in the examples.

In a particularly preferred manner, the derivatives of the invention retain at least part of the p62 protein allowing interaction with the SH2 domain of GAP. This part of p62 is more particularly composed of phosphorylated tyrosines, localized between residues 200 to 450 of the protein p62 (Cf SEQ ID No. 1). A preferred derivative according to the invention therefore comprises at least (i) a deletion in the region between residues 145 to 247 of p62 and (ii) a part of p62 allowing interaction with the SH2 domain of GAP. More preferably, the deletion relates to residues 1 to 202. In this regard, the applicant has also shown that derivatives according to the invention having particularly advantageous properties may consist of polypeptides essentially comprising the region carrying the phosphorylated tyrosines of p62.

A particularly preferred example of a polypeptide according to the invention is represented by the Δp62 polypeptide of sequence SEQ ID No. 2, having a deletion of residues 170-208 of the sequence of p62. Another example is represented by the polypeptide p62-C comprising the residues 203 to 443 of p62 (sequence SEQ ID No. 3).

The results presented in the present application show in particular that Δp62 can enter into competition with p62 with respect to GAP. GAP being one of the effectors of the Ras proteins, Δp62 blocks the mitogenic pathways which depend on it. Overexpressed by gene transfer (transfection, infection, microinjection, etc.) Δp62 induces cell death by apoptosis in normal (fibroblasts NIH3T3 and Swiss 3T3) or tumor (H460; HCT116) cells, and is capable of inhibiting the formation of foci induced by ras. This same effect is obtained with the p62-C derivative (essentially comprising the C-terminal part of Δp62, which covers the region between amino acids 203 and 443 and which corresponds to the domain of interaction with the SH2 domains of GAP and of GRB2). This C-terminal part also contains three sites for interaction with the SH3 domains, those having the most affinity for Fyn. The significant therapeutic activity of the derivatives according to the invention is linked to their multiple properties, and in particular their capacity for titrating the SH3 domains of proteins of the src family (example: fyn), their capacity for inhibiting the recruitment of GRB2 by titrating its SH2 domain, and their ability to inhibit the effector function of the GAP protein for signaling pathways which depend on Ras.

Another object of the present invention relates to any nucleic acid coding for a polypeptide as defined above. The nucleic acid according to the invention can be a ribonucleic acid (RNA) or deoxyribonucleic acid (DNA). In addition, it may be genomic DNA (gDNA) or complementary DNA (cDNA). It can be of human, animal, viral, synthetic or semi-synthetic origin. It can be obtained in different ways and in particular by chemical synthesis using the sequences presented in the application and for example a nucleic acid synthesizer. It can also be obtained by screening libraries using specific probes, in particular as described in the application (see sequences SEQ ID No. 6 and 7 for example). It can also be obtained by mixed techniques including chemical modification (elongation, deletion, substitution, etc.) of sequences screened from libraries. In general, the nucleic acids of the invention can be prepared according to any technique known to those skilled in the art. Preferably, the nucleic acid according to the invention is a cDNA or an RNA.

The nucleic acid according to the invention is advantageously chosen from: (a) all or part of the sequence SEQ ID No. 2 or SEQ ID No. 3 or their complementary strand, (b) any sequence hybridizing with the sequences (a ) and coding for a derivative according to the invention,

(c) variants of (a) and (b) resulting from the degeneration of the genetic code.

As indicated previously, the applicant has now isolated and characterized new nucleic acid sequences coding for polypeptides derived from p62, having quite remarkable antiproliferative and apoptotic properties. These nucleic acids can now be used as therapeutic agents to produce in cells derivatives according to the invention capable of destroying or correcting cellular dysfunctions. To this end, the present invention also relates to any expression cassette comprising an acid nucleic acid as defined above, a promoter allowing its expression and a transcription termination signal. The promoter is advantageously chosen from functional promoters in mammalian cells, preferably human. More preferably, it is a promoter allowing the expression of a nucleoic acid in a hyperproliferative cell (cancerous, restenosis, etc.). In this regard, different promoters can be used. It may for example be the own promoter of the p62 gene. They can also be regions of different origin (responsible for the expression of other proteins, or even synthetic). It can thus be any promoter or derived sequence stimulating or repressing the transcription of a gene in a specific way or not, inducible or not, strong or weak. Mention may in particular be made of the promoter sequences of eukaryotic or viral genes. For example, they may be promoter sequences originating from the genome of the target cell. Among the eukaryotic promoters, ubiquitous promoters can be used in particular (promoter of the HPRT, PGK genes, α-actin, tubulin, etc.), promoters of intermediate filaments (promoter of the GFAP genes, desmin, vimentin, neurofilaments, keratin, etc. ), promoters of therapeutic genes (for example the promoter of the MDR, CFTR, Factor VIII, ApoAl genes, etc.), tissue-specific promoters (promoter of the pyruvate kinase gene, villin, intestinal fatty acid binding protein, α- smooth muscle actin, etc.) or promoters responding to a stimulus (steroid hormone receptor, retinoic acid receptor, etc.). Likewise, they may be promoter sequences originating from the genome of a virus, such as for example the promoters of the E1A and MLP genes of adenovirus, the early promoter of CMV, or also the promoter of the RSV LTR, etc. . In addition, these promoter regions can be modified by adding activation or regulatory sequences, or allowing tissue-specific or majority expression. The present invention now provides new therapeutic agents which, by their iterative antiprol properties and / or apoptotics to interfere with many cellular dysfunctions. For this purpose, the nucleic acids or cassettes according to the invention can be injected as such at the site to be treated, or incubated directly with the cells to be destroyed or treated. It has in fact been described that naked nucleic acids can penetrate cells without any particular vector. Nevertheless, it is preferred in the context of the present invention to use an administration vector, making it possible to improve (i) the efficiency of cell penetration, (ii) targeting (iii) extra- and intracellular stability. In a particularly preferred embodiment of the present invention the nucleic acid or the cassette is incorporated into a vector. The vector used can be of chemical origin (liposome, nanoparticle, peptide complex, cationic lipids or polymers, etc.) viral (retrovirus, Adenovirus, herpes virus, AAV, vaccinia virus, etc.) or plasmid. The use of viral vectors is based on the natural properties of transfection of viruses. It is thus possible to use, for example, adenoviruses, herpes viruses, retroviruses and associated adeno viruses. These vectors are particularly effective in terms of transfection. In this regard, a preferred object according to the invention resides in a defective recombinant retrovirus whose genome comprises a nucleic acid as defined above. Another particular object of the invention resides in a defective recombinant adenovirus whose genome comprises a nucleic acid as defined above.

The vector according to the invention can also be a non-viral agent capable of promoting the transfer and expression of nucleic acids in eukaryotic cells. Chemical or biochemical vectors, synthetic or natural, represent an interesting alternative to natural viruses in particular for reasons of convenience, security and also by the absence of theoretical limit as regards the size of the DNA to be transfected. These synthetic vectors have two main functions, to compact the nucleic acid to be transfected and to promote its cell fixation as well as its passage through the plasma membrane and, where appropriate, the two nuclear membranes. To compensate for the polyanionic nature of nucleic acids, the non-viral vectors all have polycationic charges. The nucleic acid or vector used in the present invention can be formulated for topical, oral, parenteral, intranasal, intravenous, intramuscular, subcutaneous, intraocular, transdermal, etc. administration. Preferably, the nucleic acid or the vector is used in an injectable form. It can therefore be mixed with any pharmaceutically acceptable vehicle for an injectable formulation, in particular for a direct injection at the site to be treated. They may in particular be sterile, isotonic solutions, or dry compositions, in particular lyophilized, which, by addition as appropriate of sterilized water or physiological saline, allow the constitution of injectable solutes. A direct injection of the nucleic acid into the patient's tumor is advantageous because it allows the therapeutic effect to be concentrated in the affected tissues. The doses of nucleic acid used can be adapted according to different parameters, and in particular according to the gene, the vector, the mode of administration used, the pathology concerned or even the duration of the treatment sought.

The invention also relates to any pharmaceutical composition comprising at least one nucleic acid.

It also relates to any pharmaceutical composition comprising at least one vector as defined above. It also relates to any pharmaceutical composition comprising at least one p62 derivative as defined above.

Due to their iterative antiprol properties, the pharmaceutical compositions according to the invention are very particularly suitable for the treatment of hyperproliferative disorders, such as in particular cancers and restenosis. The present invention thus provides a particularly effective method for the destruction of cells, in particular of hyperproliferative cells. It can be used in vitro or ex vivo. Ex vivo, it essentially consists in incubating the cells in the presence of one or more nucleic acids (or of a vector, or cassette or directly of the derivative). In vivo, it consists in administering to the organism an active quantity of a vector (or of a cassette) according to the invention, preferably directly at the level of the site to be treated (tumor in particular). In this regard, the subject of the invention is also a method of destroying hyperproliferative cells comprising bringing said cells or a part of them into contact with a nucleic acid as defined above. The present invention is advantageously used in vivo for the destruction of cells in hyperprol iteration (ie in abnormal proliferation). It is thus applicable to the destruction of tumor cells or smooth muscle cells of the vascular wall (restenosis). It is particularly suitable for the treatment of cancers in which an activated oncogene is involved. By way of example, mention may be made of colon adenocarcinomas, thyroid cancers, lung carcinomas, myeloid leukemias, colorectal cancers, breast cancers, lung cancers, gastric cancers, cancer of the lungs esophagus, B lymphomas, ovarian cancer, bladder cancer, glioblastoma, hepatocarcinoma, bone, skin, pancreatic cancer, kidney and prostate cancer, etc.

The products of the invention are also useful for the identification of other partners in oncogenic signaling pathways, by searching for inhibitors, agonists, competitors or molecules interacting in vivo with these products.

Furthermore, the invention also relates to the antisense sequences, the expression of which in a target cell makes it possible to control the transcription and / or the translation of cellular mRNA coding for p62 or Δp62. Such sequences can for example be transcribed in the target cell into RNA complementary to the cellular mRNA Δp62 or p62 and thus block their translation into protein according to the technique described in patent EP 140 308. Such sequences may consist of all or part of the nucleic sequences SEQ ID No. 1, 2 or 3, transcribed in the reverse orientation . The present invention also relates to the use of any compound capable of inducing the expression or the overexpression of Δp62 in a cell for the preparation of a pharmaceutical composition intended for the treatment of hyperproliferative disorders.

The present invention will be described in more detail with the aid of the following examples, which should be considered as illustrative and not limiting.

Legends of figures

Figure 1: Schematic representation of the structural domains of p62 and Δp62. Figure 2: Effect of p62 and Δp62 on transactivation by ras proteins of an RRE derived from the enhancer of the polyome virus.

Figure 3: Demonstration of cell death induced by Δp62 in NIH3T3 fibroblasts.

Figure 4: Demonstration of the expression of Δp62 in embryonic fibroblasts treated with different cytotoxic agents and by deprivation of serum.

Figure 5: Inhibition of the formation of foci induced by oncogenes.

General molecular biology techniques

The methods conventionally used in molecular biology such as preparative extractions of plasmid DNA, centrifugation of plasmid DNA in cesium chloride gradient, electrophoresis on agarose or acrylamide gels, purification of DNA fragments by electroelution, extraction of proteins with phenol or phenol-chloroform, precipitation of DNA in saline medium with ethanol or isopropanol, the transformation in Escherichia coli, etc. are well known to those skilled in the art and are abundantly described in the literature [Maniatis T. et al., "Molecular Cloning, a Laboratory Manual", Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1982; Ausubel FM et al. (eds), "Current Protocols in Molecular Biology", John Wiley & Sons, New York, 1987].

The pBR322, pUC and phage plasmids of the M13 series are of commercial origin (Bethesda Research Laboratories). For the ligations, the DNA fragments can be separated according to their size by electrophoresis in agarose or acrylamide gels, extracted with phenol or with a phenol / chloroform mixture, precipitated with ethanol and then incubated in the presence of the DNA ligase from phage T4 (Biolabs) according to the supplier's recommendations. The filling of the protruding 5 ′ ends can be carried out by the Klenow fragment of DNA Polymerase I of E. coli (Biolabs) according to the supplier's specifications. The destruction of the protruding 3 ′ ends is carried out in the presence of the DNA polymerase of phage T4 (Biolabs) used according to the manufacturer's recommendations. The destruction of the protruding 5 ′ ends is carried out by gentle treatment with nuclease S1. Mutagenesis directed in vitro by synthetic oligodeoxynucleotides can be carried out according to the method developed by Taylor et al. [Nucleic Acids Res. 13 (1985) 8749-8764] using the kit distributed by Amersham. The enzymatic amplification of DNA fragments by the technique called PCR [Polymerase-catalyzed Chain Reaction, Saiki RK et al., Science 22Û (1985) 1350-1354; Mullis KB and Faloona FA, Meth. Enzym. 155 (1987) 335-350] can be performed using a "DNA thermal cycler" (Perkin Elmer Cetus) according to the manufacturer's specifications. Verification of the nucleotide sequences can be carried out by the method developed by Sanger et al. [Proc. Natl. Acad. Sci. USA, 74 (1977) 5463-5467] using the kit distributed by Amersham.

Examples

Example 1: Isolation of the DNA complementary to Δo62.

The complementary DNA of Δp62 was isolated by PCR on a population of complementary DNA synthesized from poly A + RNA extracted from human placenta. 1 μg of DNA was used in conjunction with the primers derived from the sequence of p62 and which cover amino acids 123 to 131 on the one hand (oligo 5 ') and 437 to 443 on the other hand (oligo 3'). The sequences of these primers are as follows: 5 'oligo: CAGCTGCTGACGGCAGAAATTGAG (SEQ ID No. 4) 3' oligo: TTAATAACGTCCATATGGGTGCTC (SEQ ID No. 5)

The reactions were carried out at 55 ° C. and gave two products separated by agarose gel electrophoresis:

- a band of 987 base pairs, which corresponds to the PCR product of p62 - a band of 870 base pairs, which corresponds to the PCR product of Δp62.

This last band was cloned and its sequence corresponds exactly to the sequence of p62, except for a deletion of 1 17 base pairs in the domain of homology to GRP33. The complete sequence of Δp62 is presented SEQ ID No. 2 (see also Figure 1).

The existence of this p62 isoform was confirmed by screening for a DNA library complementary to human placenta established in the vector λgt 1 1. The oligonucleotide used for this screening is a 24-mer corresponding to the specific junction of the deletion present in

Δp62. The sequence of this oligonucleotide is:

CAGTATCCCAAGGAGGAAGAGCTG (SEQ ID n ° 6)

Example 2: Construction of expression vectors of Δp62 and p62-C.

This example describes the construction of vectors usable for the transfer of the nucleic acids of the invention in vitro or in vivo.

2.1. Plasmid vector:

For the construction of plasmid vectors, 2 types of vectors were used. - The vector SV2, described in DNA Cloning, A practical approach

Vol. 2, DM Glover (Ed) IRL Press, Oxford, Washington DC, 1985. This vector is a eukaryotic expression vector. The nucleic acids coding for the variants p62-C and Δp62 were inserted into this vector in the form of EcoRI fragments. They are thus placed under the control of the promoter of the enhancer of the SV40 virus. - The vector pcDNA3 (Invitrogen). It is also a eukaryotic expression vector. The nucleic acids coding for the variants p62-C and Δp62, were inserted into this vector in the form of fragments

EcoRI, are thus placed under the control of the CMV early promoter.

2.2. Viral Vector

According to a particular embodiment, the invention resides in the construction and the use of viral vectors allowing the transfer and the expression in vivo of nucleic acids as defined above.

With regard more particularly to adenoviruses, various serotypes, whose structure and properties vary somewhat, have been characterized. Among these serotypes, it is preferred to use, in the context of the present invention, human adenoviruses of type 2 or 5 (Ad 2 or Ad 5) or adenoviruses of animal origin (see application WO 94/26914). Among the adenoviruses of animal origin which can be used in the context of the present invention, mention may be made of adenoviruses of canine, bovine, murine origin (example: Mav1, Beard et al., Virology 75 (1990) 81), ovine, porcine , avian or even simian (example: after-sales service). Preferably, the adenovirus of animal origin is a canine adenovirus, more preferably a CAV2 adenovirus [Manhattan strain or A26 / 61 (ATCC VR-800) for example]. Preferably, in the context of the invention, adenoviruses of human or canine or mixed origin are used.

Preferably, the defective adenoviruses of the invention comprise ITRs, a sequence allowing the encapsidation and a nucleic acid according to the invention. Even more preferably, in the genome of the adenoviruses of the invention, the E1 region at least is non-functional. The viral gene considered can be made non-functional by any technique known to a person skilled in the art, and in particular by total suppression, substitution, partial deletion, or addition of one or more bases in the gene (s) considered. Such modifications can be obtained in vitro (on isolated DNA) or in situ, for example, by means of genetic engineering techniques, or by treatment with mutagenic agents. Other regions can also be modified, and in particular the region E3 (WO95 / 02697), E2 (W094 / 28938), E4 (W094 / 28152, W094 / 12649, WO95 / 02697) and L5 (WO95 / 02697). According to a preferred embodiment, the adenovirus according to the invention comprises a deletion in the E1 and E4 regions. According to another preferred embodiment, it comprises a deletion in region E1 at the level of which the region E4 and the nucleic acid of the invention are inserted (Cf FR94 13355). In the viruses of the invention, the deletion in the E1 region preferably extends from nucleotides 455 to 3329 on the sequence of the adenovirus Ad5.

The defective recombinant adenoviruses according to the invention can be prepared by any technique known to those skilled in the art (Levrero et al., Gene 101 (1991) 195, EP 185 573; Graham, EMBO J. 3 (1984) 2917). In particular, they can be prepared by homologous recombination between an adenovirus and a plasmid carrying inter alia the DNA sequence of interest. Homologous recombination occurs after co-transfection of said adenovirus and plasmid in an appropriate cell line. The cell line used must preferably (i) be transformable by said elements, and (ii), contain the sequences capable of complementing the part of the genome of the defective adenovirus, preferably in integrated form to avoid the risks of recombination. As an example of a line, mention may be made of the human embryonic kidney line 293 (Graham et al., J. Gen. Virol. 36 (1977) 59) which contains in particular, integrated into its genome, the left part of the genome an Ad5 adenovirus (12%) or lines capable of complementing the E1 and E4 functions as described in particular in applications No. WO 94/26914 and WO95 / 02697. Then, the adenoviruses which have multiplied are recovered and purified according to conventional techniques of molecular biology, as illustrated in the examples.

Concerning adeno-associated viruses (AAV), these are DNA viruses of relatively small size, which integrate into the genome of the cells they infect, in a stable and site-specific manner. They are capable of infecting a broad spectrum of cells, without inducing an effect on cell growth, morphology or differentiation. Furthermore, they do not seem to be involved in pathologies in humans. The AAV genome has been cloned, sequenced and characterized. It comprises approximately 4,700 bases, and contains at each end an inverted repeat region (ITR) of approximately 145 bases, serving as an origin of replication for the virus. The rest of the genome is divided into 2 essential regions carrying the packaging functions: the left part of the genome, which contains the rep gene involved in viral replication and the expression of viral genes; the right part of the genome, which contains the cap gene coding for the capsid proteins of the virus.

The use of vectors derived from AAVs for gene transfer in vitro and in vivo has been described in the literature (see in particular WO 91/18088; WO 93/09239; US 4,797,368, US 5,139,941, EP 488,528). These applications describe various constructs derived from AAVs, in which the rep and / or cap genes are deleted and replaced by a gene of interest, and their use for transferring in vitro (onto cells in culture) or in vivo (directly into an organism ) said gene of interest. The defective recombinant AAVs according to the invention can be prepared by cotransfection, in a cell line infected with a human helper virus (for example an adenovirus), of a plasmid containing a nucleic sequence of the invention of interest bordered by two inverted repeat regions (ITR) of AAV, and of a plasmid carrying the packaging genes (rep and cap genes) of AAV. A cell line which can be used is, for example, line 293. The recombinant AAVs produced are then purified by conventional techniques.

Concerning herpes viruses and retroviruses, the construction of recombinant vectors has been widely described in the literature: see in particular Breakfield et al., New Biologist 3 (1991) 203; EP 453242, EP178220, Bemstein et al. Broom. Eng. 7 (1985) 235; McCormick, BioTechnology 3 (1985) 689, etc. In particular, retroviruses are integrative viruses, selectively infecting dividing cells. They therefore constitute vectors of interest for cancer applications. The genome of retroviruses essentially comprises two LTRs, an encapsidation sequence and three coding regions (gag, pol and env). In recombinant vectors derived from retroviruses, the gag, pol and env genes are generally deleted, in whole or in part, and replaced by a heterologous nucleic acid sequence of interest. These vectors can be produced from different types of retroviruses such as in particular MoMuLV

("murine moloney leukemia virus"; also designated MoMLV), MSV ("murine moloney sarcoma virus"), HaSV ("harvey sarcoma virus"); SNV ("spleen necrosis virus"); RSV ("rous sarcoma virus") or the Friend virus.

To construct recombinant retroviruses according to the invention comprising a nucleic acid according to the invention, a plasmid comprising in particular the LTRs, the packaging sequence and said nucleic acid is constructed, then used to transfect a cell line called packaging, capable to provide trans deficient retroviral functions in the plasmid. Generally, the packaging lines are therefore capable of expressing the gag, pol and env genes. Such packaging lines have been described in the prior art, and in particular the line PA317 (US 4,861, 719); the PsiCRIP line (WO 90/02806) and the GP + envAm-12 line (WO 89/07150). Furthermore, the recombinant retroviruses may include modifications at the level of the LTRs to suppress transcriptional activity, as well as extended packaging sequences comprising a part of the gag gene (Bender et al., J. Virol. 61 (1987) 1639). The recombinant retroviruses produced are then purified by conventional techniques.

For the implementation of the present invention, it is very particularly advantageous to use a defective recombinant adenovirus or retrovirus. These vectors indeed have properties which are particularly advantageous for the transfer of genes into tumor cells.

2.3. Chemical vector

Among the synthetic vectors developed, it is preferred to use, within the framework of the invention, cationic polymers of polylysine type, (LKLK) n, (LKKL) n, immine polyethylene and DEAE dextran or alternatively cationic or lipofectant lipids. They have the property of condensing DNA and promoting its association with the cell membrane. Among these, mention may be made of lipopolyamines (lipofectamine, transfectam, etc.), different cationic or neutral lipids (DOTMA, DOGS, DOPE, etc.) as well as peptides of nuclear origin. In addition, the concept of targeted transfection has been developed, mediated by a receptor, which takes advantage of the principle of condensing DNA thanks to the cationic polymer while directing the binding of the complex to the membrane thanks to a chemical coupling between the cationic polymer and the ligand of a membrane receptor, present on the surface of the cell type that is to be grafted. The targeting of the transferrin, insulin or hepatocyte asialoglycoprotein receptor has thus been described. The preparation of a composition according to the invention using such a chemical vector is carried out according to any technique known to those skilled in the art, generally by simple contacting of the various components. Example 3 Inhibition of the transactivation of RRE (ras responsive elements) due to the oncogenic forms of Ras (FIG. 2)

NIH 3T3 fibroblasts were transfected with a reporter gene, that of chloramphenicol acetyl transferase, placed under the control of Ras response elements derived from the enhancer of the polyome virus. These elements are stimulated 15 to 20 times when the cells are cotransfected with an expression vector carrying the cDNA of the SV40 Middle T (MT) oncogene. This stimulation is only slightly affected when a cotransfection provides the expression vectors of p62-C and of Δp62 (see example 2). When cotransfection is performed, no longer with MT but with the activated form of the Ha-ras oncogene (Val 12), the CAT activity is stimulated 30 to 40 times above the basic level. The expression of p62 has little effect on this stimulation, while p62-C and Δp62 almost completely inhibit any activity due to oncogenic Ras. Similarly, the stimulation obtained by cotransfection with the v-src oncogene is strongly inhibited by the proteins p62-C and Δp62, but not by p62.

These experiments were carried out with 0.5 μg of vector allowing the expression of MT or of Ras VAL12 or of v-src and 4 μg of expression vector carrying the cDNA of p62-C or of Δp62. They clearly demonstrate the power of the proteins of the invention to oppose ras oncogenic signals.

Example 4: Demonstration of cell death induced by Δp62 in NIH3T3 fibroblasts (Figure 3).

NIH3T3 fibroblasts were transfected with an efficiency of 60% with 5 μg of Δp62 expression vector (example 2). 24 hours after transfection, the cells show a significant alteration in their viability compared to the control. Analysis of their DNA reveals after migration on agarose gel degradation scales characteristic of apoptosis phenomena. The same phenomena are observed when p62-C is transfected under the same conditions as Δp62.

Example 5: Demonstration of the expression of Δp62 in embryonic fibroblasts treated with different cytotoxic agents and by deprivation of serum (Fiαure 4).

Mouse embryonic fibroblasts were cultured

(1), treated with 0.5 μg of okadaic acid (2), treated with 10 ng / ml of PMA and with 2 μg of ionomycin (3), subjected to 1 μM of staurosporine (4) or to 2 μg / ml of camptotecin (5) and finally deprived in serum.

The expression of the messenger RNAs of p62 and Δp62 in these fibroblasts and during these different treatments was analyzed. At each treatment, three points were analyzed. These points correspond to three treatment times: 6, 12 and 24 hours. Δp62 specific 5 'probe (SEQ ID No.7): CTGTCAAGCAGTATCCCAAGGAGG

5 'p62 specific probe (SEQ ID No. 8): AAGGGCTCAATGAGAGACAAAGCC

3 'common probe at p62 and Δp62 (SEQ ID n ° 9): GTATGTATCATCATATCCATATTC In fibroblasts cultured in the presence of 10% fetal calf serum (SVF), the p62 mRNA is demonstrated while the Δp62 mRNA is not detected even after 24 hours of cultivation. The situation is the same during treatment with okadaic acid. On the other hand, a strong induction of the Δp62 mRNA is observed after 6 to 12 hours of treatment with PMA and ionomycin. This mRNA is also detectable after addition of staurosporine and is very strongly induced after 12 hours of camptotecin treatment. When the embryonic fibroblasts are deprived in serum, a strong induction of Δp62 is observed at the same time as a disappearance of the p62 messenger.

These results therefore demonstrate that expression of the Δp62 mRNA is induced during certain apoptotic situations in fibroblasts.

Example 6 Inhibition by Δp62 of the formation of fovers induced by ras

This example describes another study showing that Δp62 interferes with the transformation process induced by oncogenes. More particularly, this example demonstrates that Δp62 is capable of inhibiting the formation of foci induced by different oncogenes (oncogenic ras, v-src) in NIH-3T3 cells, while p62 does not affect this phenomenon.

NIH3T3 fibroblasts were co-transfected with 0.1 μg of v-Src or Ha-Ras Val12 expression vector and with 4 mg of p62, Δp62 or empty expression vector (Example 2). The cells were maintained in a medium containing 10% newborn calf serum and the number of outbreaks was determined after fixing and staining of the cells in the presence of fuchsin phenol. The experiments were carried out in triplicate.

The results obtained are presented in FIG. 5. They show that Δp62 decreases the number of foci induced by v-src and Ha-Ras Val 12 by

About 50%. This effect reflects a specific antagonistic power of the oncogenic transformation by v-src and Ha-Ras since Δp62 does not affect the formation of foci induced by v-Raf. In addition, the effect observed is not linked to a toxicity of the product since the number of colonies resistant to neomycin after transfection with p62, Δp62 or an empty vector is comparable. These results therefore confirm the inhibitory role of the molecules of the invention in the transformation process induced by oncogenes. These results thus confirm the usefulness of these products in approaches for correcting the cellular proliferation processes induced by oncogenes, as well as as a tool for the identification of other active molecules and / or involved in the signaling pathways of these oncogenes. .

Example 7: Demonstration of an interaction with src in vivo

This example describes the study of the interaction of Δp62 with other molecules. It demonstrates that p62 and Δp62 are capable of interacting in vivo with src.

NIH3T3 fibroblasts were transfected with a p62 or Δp62 expression vector comprising a myc marker ("myc teg") (Example 2). The transfected cells were kept in asynchronous growth or blocked in the mitotic phase by treatment by nocodazole. The cells were then co-transfected with a v-Src or empty expression vector. 48 hours later, the cells were lysed and the complexes formed were immunodetected using anti-myc antibodies (antibody 9E10) and anti-Src antibodies (antibody N16).

The results obtained show that p62 and Δp62 are capable of interacting in vivo with src. Furthermore, while the interaction between p62 and src seems to occur only in mitotic cells, Δp62 significantly binds Src even in asynchronous cells. This interaction is enhanced in mitotic cells.

LIST OF SEQUENCES

(1) GENERAL INFORMATION:

(i) DEPOSITOR:

(A) NAME: RHONE POULENC RORER S.A.

(B) STREET: 20, AVENUE RAYMOND ARON

(C) CITY: ANTONY (E) COUNTRY: FRANCE

(F) POSTAL CODE: 92165

(G) TELEPHONE: (1) 40.91.69.22 (H) FAX: (1) 40.91.72.91 (ii) TITLE OF THE INVENTION: ΔP62, ITS VARIANTS, SEQUENCES

NUCLEICS AND THEIR USES

(iii) NUMBER OF SEQUENCES: 9

(iv) COMPUTER-DETACHABLE FORM:

(A) TYPE OF SUPPORT: Tape

(B) COMPUTER: IBM PC compatible

(C) OPERATING SYSTEM: PC-DOS / MS-DOS (D) SOFTWARE: Patentln Release # 1.0, Version # 1.30 (EPO)

(2) INFORMATION FOR SEQ ID NO: 1:

(i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1332 base pairs

(B) TYPE: nucleotide

(C) NUMBER OF STRANDS: single

(D) CONFIGURATION: linear (ii) TYPE OF MOLECULE: cDNA

(iii) HYPOTHETIC: NO

(iv) ANTI-SENSE: NO

(ix) CHARACTERISTIC:

(A) NAME / KEY: CDS

(B) LOCATIONS. 1332

(xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 1:

ATG CAG CGC CGG GAC GAC CCC GCC GCG CGC ATG AGC CGG TCT TCG GGC 48

Met Gin Arg Arg Asp Asp Pro Ala Ala Arg Met Ser Arg Ser Ser Gly 1 5 10 15

CGT AGC GGC TCC ATG GAC CCC TCC GGT GCC CAC CCC TCG GTG CGT CAG 96

Arg Ser Gly Ser Met Asp Pro Ser Gly Ala His Pro Ser Val Arg Gin 20 25 30

ACG CCG TCT CGG CAG CCG CCG CTG CCT CAC CGG TCC CGG GGA GGC GGA 144 Thr Pro Ser Arg Gin Pro Pro Leu Pro His Arg Ser Arg Gly Gly Gly 35 40 45

GGG GGA TCC CGC GGG GGC GCC CGG GCC TCG CCC GCC ACG CAG CCG CCA 192

Gly Gly Ser Arg Gly Gly Ala Arg Ala Ser Pro Ala Thr Gin Pro Pro 50 55 60

CCG CTG CTG CCG CCC TCG GCC ACG GGT CCC GAC GCG ACA GTG GGC GGG 240

Pro Leu Leu Pro Pro Ser Ala Thr Gly Pro Asp Ala Thr Val Gly Gly 65 70 75 80

CCA GCG CCG ACC CCG CTG CTG CCC CCC TCG GCC ACA GCC TCG GTC AAG 288

Pro Ala Pro Thr Pro Leu Leu Pro Pro Ser Ala Thr Ala Ser Val Lys

85 90 95

ATG GAG CCA GAG AAC AAG TAC CTG CCC GAA CTC ATG GCC GAG AAG GAC 336

Met Glu Pro Glu Asn Lys Tyr Leu Pro Glu Leu Met Ala Glu Lys Asp 100 105 110

TCG CTC GAC CCG TCC TTC ACT CAC GCC ATG CAG CTG CTG ACG GCA GAA 384

Ser Leu Asp Pro Ser Phe Thr His Ala Met Gin Leu Leu Thr Ala Glu 115 120 125

ATT GAG AAG ATT CAG AAA GGA GAC TCA AAA AAG GAT GAT GAG GAG AAT 432

Ile Glu Lys Ile Gin Lys Gly Asp Ser Lys Lys Asp Asp Glu Glu Asn 130 135 140

TAC TTG GAT TTA TTT TCT CAT AAG AAC ATG AAA CTG AAA GAG CGA GTG 480

Tyr Leu Asp Leu Phe Ser His Lys Asn Met Lys Leu Lys Glu Arg Val

145 150 155 160

CTG ATA CCT GTC AAG CAG TAT CCC AAG TTC AAT TTT GTG GGG AAG ATT 528

Leu Ile Pro Val Lys Gin Tyr Pro Lys Phe Asn Phe Val Gly Lys Ile

165 170 175

CTT GGA CCA CAA GGG AAT ACA ATC AAA AGA CTG CAG GAA GAG ACT GGT 576

Leu Gly Pro Gin Gly Asn Thr Ile Lys Arg Leu Gin Glu Glu Thr Gly 180 185 190

GCA AAG ATC TCT GTA TTG GGA AAG GGC TCA ATG AGA GAC AAA GCC AAG 624

Ala Lys Ile Ser Val Leu Gly Lys Gly Ser Met Arg Asp Lys Ala Lys 195 200 205

GAG GAA GAG CTG CGC AAA GGT GGA GAC CCC AAA TAT GCC CAC TTG AAT 672

Glu Glu Glu Leu Arg Lys Gly Gly Asp Pro Lys Tyr Ala His Leu Asn 210 215 220

ATG GAT CTG CAT GTC TTC ATT GAA GTC TTT GGA CCC CCA TGT GAG GCT 720 Met Asp Leu His Val Phe Ile Glu Val Phe Gly Pro Pro Cys Glu Ala 225 230 235 240

TAT GCT CTT ATG GCC CAT GCC ATG GAG GAA GTC AAG AAA TTT CTA GTA 768

Tyr Ala Leu Met Ala His Ala Met Glu Glu Val Lys Lys Phe Leu Val 245 250 255

CCG GAT ATG ATG GAT GAT ATC TGT CAG GAG CAA TTT CTA GAG CTG TCC 816

Pro Asp Met Met Asp Asp Ile Cys Gin Glu Gin Phe Leu Glu Leu Ser 260 265 270

TAC TTG AAT GGA GTA CCT GAA CCC TCT CGT GGA CGT GGG GTG CCA GTG 864

Tyr Leu Asn Gly Val Pro Glu Pro Ser Arg Gly Arg Gly Val Pro Val 275 280 285

AGA GGC CGG GGA GCT GCA CCT CCT CCA CCA CCT GTT CCC AGG GGC CGT 912

Arg Gly Arg Gly Ala Ala Pro Pro Pro Pro Pro Val Pro Arg Gly Arg

290 295 300

GGT GTT GGA CCA CCT CGG GGG GCT TTG GTA CGT GGT ACA CCA GTA AGG 960

Gly Val Gly Pro Pro Arg Gly Ala Leu Val Arg Gly Thr Pro Val Arg 305 310 315 320

GGA GCC ATC ACC AGA GGT GCC ACT GTG ACT CGA GGC GTG CCA CCC CCA 1008

Gly Ala Ile Thr Arg Gly Ala Thr Val Thr Arg Gly Val Pro Pro Pro 325 330 335

CCT ACT GTG AGG GGT GCT CCA GCA CCA AGA GCA CGG ACA GCG GGC ATC 1056

Pro Thr Val Arg Gly Ala Pro Ala Pro Arg Ala Arg Thr Ala Gly Ile 340 345 350

CAG AGG ATA CCT TTG CCT CCA CCT CCT GCA CCA GAA ACA TAT GAA GAA 1104

Gin Arg Ile Pro Leu Pro Pro Pro Pro Ala Pro Glu Thr Tyr Glu Glu 355 360 365

TAT GGA TAT GAT GAT ACA TAC GCA GAA CAA AGT TAC GAA GGC TAC GAA 1152

Tyr Gly Tyr Asp Asp Thr Tyr Ala Glu Gin Ser Tyr Glu Gly Tyr Glu 370 375 380

GGC TAT TAC AGC CAG AGT CAA GGG GAC TCA GAA TAT TAT GAC TAT GGA 1200

Gly Tyr Tyr Ser Gin Ser Gin Gly Asp Ser Glu Tyr Tyr Asp Tyr Tyr Gly

385 390 395 400

CAT GGG GAG GTT CAA GAT TCT TAT GAA GCT TAT GGC CAG GAC GAC TGG 1248

His Gly Glu Val Gin Asp Ser Tyr Glu Ala Tyr Gly Gin Asp Asp Trp 405 410 415

AAT GGG ACC AGG CCG TCG CTG AAG GCC CCT CCT GCT AGG CCA GTG AAG 1296 Asn Gly Thr Arg Pro Ser Leu Lys Ala Pro Pro Ala Arg Pro Val Lys 420 425 430

GGA GCA TAC AGA GAG CAC CCA TAT GGA CGT TAT TAA 1332

Gly Ala Tyr Arg Glu His Pro Tyr Gly Arg Tyr * 435 440

(2) INFORMATION FOR SEQ ID NO: 2:

(i) CHARACTERISTICS OF THE SEQUENCE:

(A) LENGTH: 1215 base pairs

(B) TYPE: nucleotide (C) NUMBER OF STRANDS: single

(D) CONFIGURATION: linear

(ii) TYPE OF MOLECULE: cDNA (iii) HYPOTHETIC: NO

(iv) ANTI-SENSE: NO

(ix) CHARACTERISTIC:

(A) NAME / KEY: CDS

(B) LOCATION: 1..1215

(xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 2:

ATG CAG CGC CGG GAC GAC CCC GCC GCG CGC ATG AGC CGG TCT TCG GGC 48

Met Gin Arg Arg Asp Asp Pro Ala Ala Arg Met Ser Arg Ser Ser Gly 1 5 10 15

CGT AGC GGC TCC ATG GAC CCC TCC GGT GCC CAC CCC TCG GTG CGT CAG 96

Arg Ser Gly Ser Met Asp Pro Ser Gly Ala His Pro Ser Val Arg Gin 20 25 30

ACG CCG TCT CGG CAG CCG CCG CTG CCT CAC CGG TCC CGG GGA GGC GGA 144

Thr Pro Ser Arg Gin Pro Pro Leu Pro His Arg Ser Arg Gly Gly Gly 35 40 45

GGG GGA TCC CGC GGG GGC GCC CGG GCC TCG CCC GCC ACG CAG CCG CCA 192

Gly Gly Ser Arg Gly Gly Ala Arg Ala Ser Pro Ala Thr Gin Pro Pro 50 55 60

CCG CTG CTG CCG CCC TCG GCC ACG GGT CCC GAC GCG ACA GTG GGC GGG 240

Pro Leu Leu Pro Pro Ser Ala Thr Gly Pro Asp Ala Thr Val Gly Gly 65 70 75 80

CCA GCG CCG ACC CCG CTG CTG CCC CCC TCG GCC ACA GCC TCG GTC AAG 288

Pro Ala Pro Thr Pro Leu Leu Pro Pro Ser Ala Thr Ala Ser Val Lys 85 90 95 ATG GAG CCA GAG AAC AAG TAC CTG CCC GAA CTC ATG GCC GAG AAG GAC 336

Met Glu Pro Glu Asn Lys Tyr Leu Pro Glu Leu Met Ala Glu Lys Asp 100 105 110

TCG CTC GAC CCG TCC TTC ACT CAC GCC ATG CAG CTG CTG ACG GCA GAA 384

Ser Leu Asp Pro Ser Phe Thr His Ala Met Gin Leu Leu Thr Ala Glu 115 120 125

ATT GAG AAG ATT CAG AAA GGA GAC TCA AAA AAG GAT GAT GAG GAG AAT 432

Ile Glu Lys Ile Gin Lys Gly Asp Ser Lys Lys Asp Asp Glu Glu Asn 130 ^• 135 140

TAC TTG GAT TTA TTT TCT CAT AAG AAC ATG AAA CTG AAA GAG CGA GTG 480

Tyr Leu Asp Leu Phe Ser His Lys Asn Met Lys Leu Lys Glu Arg Val 145 150 155 160

CTG ATA CCT GTC AAG CAG TAT CCC AAG GAG GAA GAG CTG CGC AAA GGT 528

Leu Ile Pro Val Lys Gin Tyr Pro Lys Glu Glu Glu Leu Arg Lys Gly 165 170 175

GGA GAC CCC AAA TAT GCC CAC TTG AAT ATG GAT CTG CAT GTC TTC ATT 576

Gly Asp Pro Lys Tyr Ala His Leu Asn Met Asp Leu His Val Phe Ile 180 185 190

GAA GTC TTT GGA CCC CCA TGT GAG GCT TAT GCT CTT ATG GCC CAT GCC 624

Glu Val Phe Gly Pro Pro Cys Glu Ala Tyr Ala Leu Met Ala His Ala 195 200 205

ATG GAG GAA GTC AAG AAA TTT CTA GTA CCG GAT ATG ATG GAT GAT ATC 672

Met Glu Glu Val Lys Lys Phe Leu Val Pro Asp Met Met Asp Asp Ile 210 215 220

TGT CAG GAG CAA TTT CTA GAG CTG TCC TAC TTG AAT GGA GTA CCT GAA 720

Cys Gin Glu Gin Phe Leu Glu Leu Ser Tyr Leu Asn Gly Val Pro Glu 225 230 235 240

CCC TCT CGT GGA CGT GGG GTG CCA GTG AGA GGC CGG GGA GCT GCA CCT 768

Pro Ser Arg Gly Arg Gly Val Pro Val Arg Gly Arg Gly Ala Ala Pro 245 250 255

CCT CCA CCA CCT GTT CCC AGG GGC CGT GGT GTT GGA CCA CCT CGG GGG 816

Pro Pro Pro Pro Val Pro Arg Gly Arg Gly Val Gly Pro Pro Arg Gly 260 265 270

GCT TTG GTA CGT GGT ACA CCA GTA AGG GGA GCC ATC ACC AGA GGT GCC 864

Ala Leu Val Arg Gly Thr Pro Val Arg Gly Ala Ile Thr Arg Gly Ala 275 280 285 ACT GTG ACT CGA GGC GTG CCA CCC CCA CCT ACT GTG AGG GGT GCT CCA 912

Thr Val Thr Arg Gly Val Pro Pro Pro Pro Thr Val Arg Gly Ala Pro 290 295 300

GCA CCA AGA GCA CGG ACA GCG GGC ATC CAG AGG ATA CCT TTG CCT CCA 960

Ala Pro Arg Ala Arg Thr Ala Gly Ile Gin Arg Ile Pro Leu Pro Pro 305 310 315 320

CCT CCT GCA CCA GAA ACA TAT GAA GAA TAT GGA TAT GAT GAT ACA TAC 1008

Pro Pro Ala Pro Glu Thr Tyr Glu Glu Tyr Gly Tyr Asp Asp Thr Tyr 325 330 335

GCA GAA CAA AGT TAC GAA GGC TAC GAA GGC TAT TAC AGC CAG AGT CAA 1056

Ala Glu Gin Ser Tyr Glu Gly Tyr Glu Gly Tyr Tyr Ser Gin Ser Gin 340 345 350

GGG GAC TCA GAA TAT TAT GAC TAT GGA CAT GGG GAG GTT CAA GAT TCT 1104

Gly Asp Ser Glu Tyr Tyr Asp Tyr Gly His Gly Glu Val Gin Asp Ser 355 360 365

TAT GAA GCT TAT GGC CAG GAC GAC TGG AAT GGG ACC AGG CCG TCG CTG 1152

Tyr Glu Ala Tyr Gly Gin Asp Asp Trp Asn Gly Thr Arg Pro Ser Leu 370 375 380

AAG GCC CCT CCT GCT AGG CCA GTG AAG GGA GCA TAC AGA GAG CAC CCA 1200

Lys Ala Pro Pro Ala Arg Pro Val Lys Gly Ala Tyr Arg Glu His Pro 385 390 395 400

TAT GGA CGT TAT TAA 1215

Tyr Gly Arg Tyr * 405

(2) INFORMATION FOR SEQ ID NO: 3:

(i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 726 base pairs

(B) TYPE: nucleotide

(C) NUMBER OF STRANDS: single

(D) CONFIGURATION: linear (ii) TYPE OF MOLECULE: cDNA (iii) HYPOTHETIC: NO (iv) ANTI-SENSE: NO

(ix) CHARACTERISTIC:

(A) NAME / KEY: CDS

(B) LOCATION: 1..726 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 3:

ATG AGA GAC AAA GCC AAG GAG GAA GAG CTG CGC AAA GGT GGA GAC CCC 48

Met Arg Asp Lys Ala Lys Glu Glu Glu Leu Arg Lys Gly Gly Asp Pro 1 5 10 15

AAA TAT GCC CAC TTG AAT ATG GAT CTG CAT GTC TTC ATT GAA GTC TTT 96

Lys Tyr Ala His Leu Asn Met Asp Leu His Val Phe Ile Glu Val Phe 20 25 30

GGA CCC CCA TGT GAG GCT TAT GCT CTT ATG GCC CAT GCC ATG GAG GAA 144

Gly Pro Pro Cys Glu Ala Tyr Ala Leu Met Ala His Ala Met Glu Glu 35 40 45

GTC AAG AAA TTT CTA GTA CCG GAT ATG ATG GAT GAT ATC TGT CAG GAG 192

Val Lys Lys Phe Leu Val Pro Asp Met Met Asp Asp Ile Cys Gin Glu 50 55 60

CAA TTT CTA GAG CTG TCC TAC TTG AAT GGA GTA CCT GAA CCC TCT CGT 240

Gin Phe Leu Glu Leu Ser Tyr Leu Asn Gly Val Pro Glu Pro Ser Arg 65 70 75 80

GGA CGT GGG GTG CCA GTG AGA GGC CGG GGA GCT GCA CCT CCT CCA CCA 288

Gly Arg Gly Val Pro Val Arg Gly Arg Gly Ala Ala Pro Pro Pro Pro 85 90 95

CCT GTT CCC AGG GGC CGT GGT GTT GGA CCA CCT CGG GGG GCT TTG GTA 336

Pro Val Pro Arg Gly Arg Gly Val Gly Pro Pro Arg Gly Ala Leu Val

100 105 110

CGT GGT ACA CCA GTA AGG GGA GCC ATC ACC AGA GGT GCC ACT GTG ACT 384

Arg Gly Thr Pro Val Arg Gly Ala Ile Thr Arg Gly Ala Thr Val Thr 115 120 125

CGA GGC GTG CCA CCC CCA CCT ACT GTG AGG GGT GCT CCA GCA CCA AGA 432

Arg Gly Val Pro Pro Pro Pro Thr Val Arg Gly Ala Pro Ala Pro Arg 130 135 140

GCA CGG ACA GCG GGC ATC CAG AGG ATA CCT TTG CCT CCA CCT CCT GCA 480

Ala Arg Thr Ala Gly Ile Gin Arg Ile Pro Leu Pro Pro Pro Pro Ala 145, 150 155 160

CCA GAA ACA TAT GAA GAA TAT GGA TAT GAT GAT ACA TAC GCA GAA CAA 528

Pro Glu Thr Tyr Glu Glu Tyr Gly Tyr Asp Asp Thr Thr Ala Glu Gin

165 170 175

AGT TAC GAA GGC TAC GAA GGC TAT TAC AGC CAG AGT CAA GGG GAC TCA 576 Ser Tyr Glu Gly Tyr Glu Gly Tyr Tyr Ser Gin Ser Gin Gly Asp Ser 180 185 190

GAA TAT TAT GAC TAT GGA CAT GGG GAG GTT CAA GAT TCT TAT GAA GCT 624

Glu Tyr Tyr Asp Asp Gly His Gly Glu Val Gin Asp Ser Tyr Glu Ala 195 200 205

TAT GGC CAG GAC GAC TGG AAT GGG ACC AGG CCG TCG CTG AAG GCC CCT 672

Tyr Gly Gin Asp Asp Trp Asn Gly Thr Arg Pro Ser Leu Lys Ala Pro

210 215 220

CCT GCT AGG CCA GTG AAG GGA GCA TAC AGA GAG CAC CCA TAT GGA CGT 720

Pro Ala Arg Pro Val Lys Gly Ala Tyr Arg Glu His Pro Tyr Gly Arg 225 230 235 240

TAT TAA 726

Tire *

(2) INFORMATION FOR SEQ ID NO: 4:

(i) CHARACTERISTICS OF THE SEQUENCE:

(A) LENGTH: 24 base pairs

(B) TYPE: nucleotide (C) NUMBER OF STRANDS: single

(D) CONFIGURATION: linear

(ii) TYPE OF MOLECULE: cDNA (iii) HYPOTHETIC: NO

(iv) ANTI-SENSE: NO

(xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 4:

CAGCTGCTGA CGGCAGAAAT TGAG 24

(2) INFORMATION FOR SEQ ID NO: 5: (i) CHARACTERISTICS OF THE SEQUENCE:

(A) LENGTH: 24 base pairs

(B) TYPE: nucleotide

(C) NUMBER OF STRANDS: single

(D) CONFIGURATION: linear

(ii) TYPE OF MOLECULE: cDNA

(iii) HYPOTHETIC: NO (iv) ANTI-SENSE: NO (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 5:

TTAATAACGT CCATATGGGT GCTC

24

(2) INFORMATION FOR SEQ ID NO: 6:

(i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 24 base pairs (B) TYPE: nucleotide

(C) NUMBER OF STRANDS: single

(D) CONFIGURATION: linear

(ii) TYPE OF MOLECULE: cDNA (iii) HYPOTHETIC: NO (iv) ANTI-SENSE: NO

(xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 6: CAGTATCCCA AGGAGGAAGA GCTG

24

(2) INFORMATION FOR SEQ ID NO: 7:

(i) CHARACTERISTICS OF THE SEQUENCE:

(A) LENGTH: 24 base pairs

(B) TYPE: nucleotide

(C) NUMBER OF STRANDS: simple (D) CONFIGURATION: linear

(ii) TYPE OF MOLECULE: cDNA

(iii) HYPOTHETIC: NO

(iv) ANTI-SENSE: NO

(xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 7:

CTGTCAAGCA GTATCCCAAG GAGG

24

(2) INFORMATION FOR SEQ ID NO: 8: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 24 base pairs

(B) TYPE: nucleotide

(C) NUMBER OF STRANDS: single

(D) CONFIGURATION: linear

(ii) TYPE OF MOLECULE: cDNA

(iii) HYPOTHETIC: NO (iv) ANTI-SENSE: NO

(xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 8: AAGGGCTCAA TGAGAGACAA AGCC

(2) INFORMATION FOR SEQ ID NO: 9:

(C) NUMBER OF STRANDS: single

(D) CONFIGURATION: linear

(ii) TYPE OF MOLECULE: cDNA (iii) HYPOTHETIC: NO (iv) ANTI-SENSE: NO

(xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 9: GTATGTATCA TCATATCCAT ATTC

24

Claims

1. P62 derivative capable of at least partially inhibiting the interaction between a GAP protein and p62.

2. A derivative according to claim 1 characterized in that it at least partially inhibits the signals transduced by ras.

3. P62 derivative characterized in that it has lost the capacity of p62 to interact with TARN.

4. Derivative according to one of claims 1 to 3 characterized in that it comprises at least one deletion in the zone of homology to the GRP33 protein.

5. Derivative according to claim 1 to 4 characterized in that it comprises a part of p62 allowing interaction with the SH2 domain of GAP.

6. Derivative according to claim 5 characterized in that it is a polypeptide comprising all or part of the sequence SEQ ID No. 2 or a variant thereof.

7. Δp62 polypeptide of sequence SEQ ID No. 2.

8. A derivative according to claim 5 characterized in that it essentially comprises the region carrying the phosphorylated tyrosines of p62.

9. Derivative according to your claim 8 characterized in that it is a polypeptide comprising all or part of the sequence SEQ ID No. 3.

10. Polypeptide p62-C of sequence SEQ ID No. 3.

11. Nucleic acid coding for a polypeptide according to one of claims 1 to 10.

12. Nucleic acid according to claim 11 characterized in that it is a cDNA or an RNA.

13. Nucleic acid according to claim 11 or 12 characterized in that it is chosen from: (a) all or part of the sequence SEQ ID No. 2 or SEQ ID No. 3 or their complementary strand,

(b) any sequence hybridizing with the sequences (a) and coding for a derivative according to claim 1,

14. Nucleic acid of sequence SEQ ID No. 2.

15. Nucleic acid of sequence SEQ ID No. 3.

16. Expression cassette comprising a nucleic acid according to one of claims 11 to 15, a promoter allowing its expression and a transcription termination signal.

17. Vector comprising a nucleic acid according to one of claims 11 to 15 or a cassette according to claim 16.

18. Vector according to claim 17 characterized in that it is a plasmid vector.

19. Vector according to claim 17 characterized in that it is a viral vector.

20. Vector according to claim 19 characterized in that the viral vector is derived from an adenovirus, a retrovirus, an AAV virus or a herpes virus.

21. Defective recombinant retrovirus whose genome comprises a nucleic acid according to one of claims 11 to 15 or a cassette according to claim 16.

22. Defective recombinant adenovirus, the genome of which comprises a nucleic acid according to one of claims 11 to 15 or a cassette according to claim 16.

23. Pharmaceutical composition comprising at least one nucleic acid according to claim 11.

24. Pharmaceutical composition comprising at least one vector according to claim 17.

25. Pharmaceutical composition comprising at least one derivative according to claim 1.

26. Pharmaceutical composition according to claims 23 to 25 for the treatment of cancers.

27. Use of a nucleic acid according to claim 11 or a vector according to claim 17 for the preparation of a pharmaceutical composition intended for the treatment of hyperproliferative disorders.